Rasagiline 0.5 MG Oral Tablet — RxCUI 636664
RxNorm drug concept · Semantic clinical drug
RxCUI 636664
Semantic clinical drug · SCD
● Current RxNorm concept 31 FDA products
47 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI636664
Official nameRasagiline 0.5 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asrasagiline (as rasagiline mesylate) 0.5 MG Oral Tablet
FDA products mapped31
Package NDCs mapped47
Reported Medicaid activity (SDUD)1,282 prescriptions · 10 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Rasagiline: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- It treats Parkinson’s disease. Your doctor may prescribe it alone or along with other Parkinson’s medicines such as levodopa.
- You take one tablet by mouth once a day, with or without food. Follow your prescriber’s directions and do not take more than prescribed, since higher doses raise the risk of high b...
- You don’t need a strict diet at recommended doses. But avoid foods with very large amounts of tyramine, like aged cheeses such as Stilton, because they can cause a dangerous blood...
- Always ask me first. Some cough medicines with dextromethorphan, tramadol, meperidine, methadone, St. John’s wort, cyclobenzaprine, and other MAO inhibitors must not be used with i...
🕸️ Concept Web — How Rasagiline 0.5 MG Oral Tablet Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Rasagiline 0.5 MG Oral Tablet
RxCUI 636664 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Rasagiline
134748IN
-
Rasagiline
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Azilect
635985BN
-
Azilect
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Rasagiline Oral Tablet
608327SCDF -
Rasagiline Oral Product
1157905SCDG -
Rasagiline Pill
1157906SCDG -
Rasagiline Oral Tablet [Azilect]
637184SBDF -
Azilect Oral Product
1176323SBDG -
Azilect Pill
1176324SBDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG - +1 more in this family
-
Rasagiline Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Rasagiline 0.5 MG
636663SCDC -
Rasagiline 0.5 MG Oral Tablet [Azilect]
637218SBD -
Rasagiline 0.5 MG [Azilect]
637217SBDC
-
Rasagiline 0.5 MG
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Rasagiline 0.5 MG
SCDC · 636663 -
Rasagiline Oral Tablet
SCDF · 608327 -
Rasagiline Oral Product
SCDG · 1157905 -
Rasagiline Pill
SCDG · 1157906
Brand-Name Concepts
-
Rasagiline 0.5 MG Oral Tablet [Azilect]
SBD · 637218 -
Rasagiline 0.5 MG [Azilect]
SBDC · 637217 -
Rasagiline Oral Tablet [Azilect]
SBDF · 637184 -
Azilect Oral Product
SBDG · 1176323 -
Azilect Pill
SBDG · 1176324 -
Azilect
BN · 635985
📦 FDA Products & Package NDCs
31 products · 47 package NDCs
47 package NDCs map to RxCUI 636664 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00093-3060-56 | 30 TABLET in 1 BOTTLE (0093-3060-56) | Rasagiline | Teva Pharmaceuticals USA, Inc. | 2017-01-03 |
| 00093-3061-56 | 30 TABLET in 1 BOTTLE (0093-3061-56) | Rasagiline | Teva Pharmaceuticals USA, Inc. | 2017-01-03 |
| 13668-0446-05 | 500 TABLET in 1 CONTAINER (13668-446-05) | RASAGILINE | Torrent Pharmaceuticals Limited | 2025-11-15 |
| 13668-0446-30 | 30 TABLET in 1 CONTAINER (13668-446-30) | RASAGILINE | Torrent Pharmaceuticals Limited | 2025-11-15 |
| 13668-0446-90 | 90 TABLET in 1 CONTAINER (13668-446-90) | RASAGILINE | Torrent Pharmaceuticals Limited | 2025-11-15 |
| 13668-0447-05 | 500 TABLET in 1 CONTAINER (13668-447-05) | RASAGILINE | Torrent Pharmaceuticals Limited | 2025-11-15 |
| 13668-0447-30 | 30 TABLET in 1 CONTAINER (13668-447-30) | RASAGILINE | Torrent Pharmaceuticals Limited | 2025-11-15 |
| 13668-0447-90 | 90 TABLET in 1 CONTAINER (13668-447-90) | RASAGILINE | Torrent Pharmaceuticals Limited | 2025-11-15 |
| 16714-0770-01 | 30 TABLET in 1 BOTTLE (16714-770-01) | Rasagiline | NorthStar RxLLC | 2018-04-17 |
| 16714-0771-01 | 30 TABLET in 1 BOTTLE (16714-771-01) | Rasagiline | NorthStar RxLLC | 2018-04-17 |
| 23155-0746-03 | 30 TABLET in 1 BOTTLE (23155-746-03) | Rasagiline mesylate | Avet Pharmaceuticals Inc. | 2023-10-23 |
| 23155-0747-03 | 30 TABLET in 1 BOTTLE (23155-747-03) | Rasagiline mesylate | Avet Pharmaceuticals Inc. | 2023-10-23 |
| 33342-0308-07 | 30 TABLET in 1 BOTTLE (33342-308-07) | Rasagiline | Macleods Pharmaceuticals Limited | 2024-06-29 |
| 33342-0309-07 | 30 TABLET in 1 BOTTLE (33342-309-07) | Rasagiline | Macleods Pharmaceuticals Limited | 2024-06-29 |
| 42571-0220-05 | 500 TABLET in 1 BOTTLE (42571-220-05) | RASAGILINE | Micro Labs Limited | 2019-04-03 |
| 42571-0220-10 | 1000 TABLET in 1 BOTTLE (42571-220-10) | RASAGILINE | Micro Labs Limited | 2019-04-03 |
| 42571-0220-30 | 30 TABLET in 1 BOTTLE (42571-220-30) | RASAGILINE | Micro Labs Limited | 2019-04-03 |
| 42571-0221-05 | 500 TABLET in 1 BOTTLE (42571-221-05) | RASAGILINE | Micro Labs Limited | 2019-04-03 |
| 42571-0221-10 | 1000 TABLET in 1 BOTTLE (42571-221-10) | RASAGILINE | Micro Labs Limited | 2019-04-03 |
| 42571-0221-30 | 30 TABLET in 1 BOTTLE (42571-221-30) | RASAGILINE | Micro Labs Limited | 2019-04-03 |
| 47781-0683-30 | 30 TABLET in 1 BOTTLE, PLASTIC (47781-683-30) | Rasagiline | Alvogen, Inc. | 2019-03-01 |
| 47781-0690-30 | 30 TABLET in 1 BOTTLE, PLASTIC (47781-690-30) | Rasagiline | Alvogen, Inc. | 2019-03-01 |
| 51407-0008-30 | 30 TABLET in 1 BOTTLE (51407-008-30) | Rasagiline | Golden State Medical Supply, Inc. | 2026-04-06 |
| 51407-0009-30 | 30 TABLET in 1 BOTTLE (51407-009-30) | Rasagiline | Golden State Medical Supply, Inc. | 2026-04-06 |
| 62135-0676-30 | 30 TABLET in 1 BOTTLE (62135-676-30) | Rasagiline | Chartwell RX, LLC | 2024-05-01 |
| 62135-0677-30 | 30 TABLET in 1 BOTTLE (62135-677-30) | Rasagiline | Chartwell RX, LLC | 2024-05-01 |
| 64980-0711-30 | 30 TABLET in 1 BOTTLE (64980-711-30) | Rasagiline | Rising Pharma Holdings, Inc. | 2025-07-21 |
| 64980-0712-30 | 30 TABLET in 1 BOTTLE (64980-712-30) | Rasagiline | Rising Pharma Holdings, Inc. | 2025-07-21 |
| 67877-0259-30 | 30 TABLET in 1 BOTTLE (67877-259-30) | Rasagiline | Ascend Laboratories, LLC | 2017-10-30 |
| 67877-0260-30 | 30 TABLET in 1 BOTTLE (67877-260-30) | Rasagiline | Ascend Laboratories, LLC | 2017-10-30 |
| 68546-0142-56 | 30 TABLET in 1 BOTTLE (68546-142-56) | Azilect | Teva Neuroscience, Inc. | 2006-07-10 |
| 68546-0229-56 | 30 TABLET in 1 BOTTLE (68546-229-56) | Azilect | Teva Neuroscience, Inc. | 2006-07-10 |
| 70518-4683-00 | 50 POUCH in 1 BOX (70518-4683-0) / 1 TABLET in 1 POUCH (705... | Rasagiline | REMEDYREPACK INC. | 2026-06-26 |
| 71921-0407-33 | 30 TABLET in 1 BOTTLE (71921-407-33) | Rasagiline mesylate | Florida Pharmaceutical Products, LLC | 2026-04-14 |
| 71921-0408-33 | 30 TABLET in 1 BOTTLE (71921-408-33) | Rasagiline mesylate | Florida Pharmaceutical Products, LLC | 2026-04-14 |
| 80005-0141-08 | 30 TABLET in 1 BOTTLE (80005-141-08) | Rasagiline | Carnegie Pharmaceuticals LLC | 2026-01-15 |
| 80005-0141-10 | 90 TABLET in 1 BOTTLE (80005-141-10) | Rasagiline | Carnegie Pharmaceuticals LLC | 2026-01-15 |
| 80005-0141-14 | 500 TABLET in 1 BOTTLE (80005-141-14) | Rasagiline | Carnegie Pharmaceuticals LLC | 2026-01-15 |
| 80005-0142-08 | 30 TABLET in 1 BOTTLE (80005-142-08) | Rasagiline | Carnegie Pharmaceuticals LLC | 2026-01-15 |
| 80005-0142-10 | 90 TABLET in 1 BOTTLE (80005-142-10) | Rasagiline | Carnegie Pharmaceuticals LLC | 2026-01-15 |
| 80005-0142-14 | 500 TABLET in 1 BOTTLE (80005-142-14) | Rasagiline | Carnegie Pharmaceuticals LLC | 2026-01-15 |
| 83085-0007-10 | 1000 TABLET in 1 BOTTLE (83085-007-10) | Rasagiline | SKG Pharma Inc. | 2025-04-04 |
| 83085-0007-30 | 30 TABLET in 1 BOTTLE (83085-007-30) | Rasagiline | SKG Pharma Inc. | 2025-04-04 |
| 83085-0007-50 | 500 TABLET in 1 BOTTLE (83085-007-50) | Rasagiline | SKG Pharma Inc. | 2025-04-04 |
| 83085-0008-10 | 1000 TABLET in 1 BOTTLE (83085-008-10) | Rasagiline | SKG Pharma Inc. | 2025-04-04 |
| 83085-0008-30 | 30 TABLET in 1 BOTTLE (83085-008-30) | Rasagiline | SKG Pharma Inc. | 2025-04-04 |
| 83085-0008-50 | 500 TABLET in 1 BOTTLE (83085-008-50) | Rasagiline | SKG Pharma Inc. | 2025-04-04 |
Observed labelers:
Carnegie Pharmaceuticals LLC (6) ·
Micro Labs Limited (6) ·
SKG Pharma Inc. (6) ·
Torrent Pharmaceuticals Limited (6) ·
Alvogen, Inc. (2) ·
Ascend Laboratories, LLC (2)
· +10 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.